EICHOR About Solutions

Recruiting studies: Squamous Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 312 location(s) · AstraZeneca · NCT06692738 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Phase N/A · 57 location(s) · Guardant Health, Inc. · NCT05059444 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · 317 location(s) · AbbVie · NCT04928846 A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With
EARLY_Phase 1 · 1 location(s) · People's Hospital of Quzhou · NCT07647094 Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT03199651 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet
Phase 2 · 71 location(s) · Bristol-Myers Squibb · NCT07680764 A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Phase 1/Phase 2 · 8 location(s) · LigaChem Biosciences, Inc. · NCT05941507 A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Phase 1/Phase 2 · 41 location(s) · Alentis Therapeutics AG · NCT06747585 A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403 A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid M
Phase 1 · 2 location(s) · Zelluna Immunotherapy AS · NCT07613723 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168 Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer
Phase 1/Phase 2 · 73 location(s) · Pfizer · NCT07227298 A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632 A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · 21 location(s) · Clasp Therapeutics, Inc. · NCT06778863 A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Ce
Phase 3 · 215 location(s) · Merck Sharp & Dohme LLC · NCT06422143 A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 · 8 location(s) · ALX Oncology Inc. · NCT07085091 GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
Phase N/A · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07511413 First in Human Study of SIM0610 in Solid Tumors
Phase 1 · 7 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07348211 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 4 location(s) · One-carbon Therapeutics AB · NCT07151040 MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760 A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · InduPro, Inc. · NCT07602842 A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants Wit
Phase 1 · 48 location(s) · BeOne Medicines · NCT06427941 FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 · 5 location(s) · Fate Therapeutics · NCT07216105 Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05011487 Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patient
Phase 2 · 1 location(s) · Qian Chu · NCT06001151 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation
Phase 3 · 2 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07416994

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →